HomeNewsIndiaIndia battles supply snags in race to build affordable ventilators

India battles supply snags in race to build affordable ventilators

Ventilators help patients breathe and are seen as critical given severe COVID-19 can lead to pneumonia and lung damage.

April 22, 2020 / 16:18 IST
Story continues below Advertisement
Representative image
Representative image

Indian medical device makers, racing to churn out ventilators as domestic COVID-19 cases spike, have been beset by supply bottlenecks, cost overruns and labour shortages that are delaying their efforts to produce an affordable device.

Ventilators help patients breathe and are seen as critical given severe COVID-19 can lead to pneumonia and lung damage. Experts warn India may run out of devices as it has fewer than 50,000 and may need 20 times that in a peak infection scenario.

Story continues below Advertisement

Companies, including Bengaluru-based Dynamatic, startup Nocca Robotics and New Delhi's AgVa Healthcare, are rushing to fill the expected supply gap with stripped-down ventilators, priced between $33 and $7,000.

Top-end ventilators can cost up to $16,000 in India.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show